Forward Pharma A/S (NASDAQ:FWP) released its earnings results on Monday. The biotechnology company reported $0.00 EPS for the quarter.
Shares of Forward Pharma A/S (NASDAQ:FWP) traded down 1.56% during mid-day trading on Friday, reaching $19.50. 40,813 shares of the company’s stock traded hands. The firm’s 50-day moving average is $24.52 and its 200 day moving average is $22.54. Forward Pharma A/S has a one year low of $14.89 and a one year high of $33.00. The firm’s market cap is $918.47 million.
FWP has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, March 21st. Jefferies Group LLC reiterated a “hold” rating and issued a $41.00 target price on shares of Forward Pharma A/S in a research note on Friday, March 31st. JMP Securities cut shares of Forward Pharma A/S from an “outperform” rating to a “market perform” rating in a research note on Monday, April 3rd. Finally, Leerink Swann set a $28.00 target price on shares of Forward Pharma A/S and gave the stock a “buy” rating in a research note on Monday, April 3rd.
COPYRIGHT VIOLATION WARNING: “Forward Pharma A/S (FWP) Releases Quarterly Earnings Results” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/04/21/forward-pharma-as-fwp-to-release-quarterly-earnings-on-monday-updated.html.
About Forward Pharma A/S
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.